Standout Papers

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population... 2022 2026 2023 2024191
  1. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial (2022)
    Takashi Kadowaki, Joakim Isendahl et al. The Lancet Diabetes & Endocrinology

Immediate Impact

3 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Tirzepatide for Obesity Treatment and Diabetes Prevention
2024 Standout
Obesity in adults
2024 Standout
4 intermediate papers

Works of Usman Khalid being referenced

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
2022 Standout

Author Peers

Author Last Decade Papers Cites
Usman Khalid 406 267 240 288 96 2.0k
Meng Liu 210 249 157 272 147 2.4k
A. Postiglione 606 153 301 300 72 1.8k
Hoon Young Choi 413 294 190 211 90 2.5k
Jing‐Yang Huang 344 480 260 235 276 2.9k
Martina Mittlboeck 720 340 123 130 69 2.8k
Yun Kyu Oh 360 678 196 174 144 2.6k
Hiroyuki Azuma 351 250 306 146 89 2.2k
Tiebin Liu 379 463 244 249 62 2.6k
Αreti Triantafyllou 423 174 445 172 118 1.8k
Matthew Traylor 237 230 167 186 55 2.2k

All Works

Loading papers...

Rankless by CCL
2026